Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SGN-30 (monoclonal antibody), SGN-30 (anti-CD30 mAb)
SGN-30 · 3 trials · 7 indications
| Name | Type | Description |
|---|---|---|
| SGN-30 | DRUG | - |
| SGN-30 (anti-CD30 mAb) | DRUG | - |
| SGN-30 (monoclonal antibody) | DRUG | - |
Inclusion Criteria * Patients must have a definite diagnosis. * Patients must be histologically confirmed CD30 positive within 3 months of enrollment * Patients with pcALCL must have target lesions present for at least 1 month without spontaneous regression * pcALCL patients must have failed treatm...
SGN-30 is an investigational monoclonal antibody developed by Pfizer, Inc. (PFE) for the treatment of CD30-positive lymphomas, including anaplastic large-cell lymphoma, Hodgkin disease, and large cell lymphoma. It is a Phase 2 oncology candidate that has been studied in patients with refractory or recurrent hematologic malignancies.
SGN-30 has been studied in anaplastic large-cell lymphoma, Hodgkin disease, and large cell lymphoma, including primary cutaneous anaplastic large cell lymphoma and refractory or recurrent CD30-positive hematologic malignancies. It is an investigational agent and is not an approved therapy for these conditions.
SGN-30 targets TNFRSF8, also known as CD30, a receptor expressed on certain lymphoma cells. It is an agonist monoclonal antibody directed against this target, which is why the clinical program focused on CD30-positive hematologic malignancies such as anaplastic large-cell lymphoma and Hodgkin disease.
SGN-30 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer holds the development program for this anti-CD30 monoclonal antibody across its lymphoma indications.
SGN-30 is in Phase 2 development. It is an investigational monoclonal antibody and has not been approved by the FDA. Its clinical program includes completed Phase 1 and Phase 2 studies in CD30-positive lymphomas, and no trials are currently active.
SGN-30 has been evaluated in completed studies including NCT00099255 in primary cutaneous anaplastic large cell lymphoma, NCT00079755 in refractory or recurrent anaplastic large cell lymphoma, and NCT00051597 in refractory or recurrent CD30-positive hematologic malignancies. These trials enrolled patients 18 years and older in the United States.
Yes. SGN-30, SGN-30 (monoclonal antibody), and SGN-30 (anti-CD30 mAb) refer to the same investigational agent. The alternate names describe its format as a monoclonal antibody directed against CD30, so searches using any of these names point to the same Pfizer development program.